Single Nucleotide Polymorphisms Genotyping Market

Market Overview

The global single nucleotide polymorphisms genotyping market size was valued at USD 9.6 billion in 2023 and is projected to reach a value of USD 22.8 billion by 2032, registering a CAGR of 10.0% during the forecast period (2024-2032). Genomic research, genetic disorders, personalized medicine, the pharmaceutical industry, and growing demand for molecular diagnostics drive the Single Nucleotide Polymorphisms Genotyping Market share. 

Single-nucleotide polymorphism (SNP) genotyping identifies and analyzes differences in single nucleotide positions within DNA sequences between individuals or populations. SNPs are the most common genetic variation, resulting from differences in a single nucleotide (A, T, C, or G) in the genome between individuals. These differences can affect traits, disease susceptibility, drug response, and other biological characteristics. The growing demand for SNP genotyping due to increased genotype research and development activities and bioinformatics in the development of diagnostic tools or effective therapeutics for various diseases is one of the key factors driving market growth.

Furthermore, the growing use of SNP genotyping in the etiology of various human diseases, including cancer, cardiovascular disease, Alzheimer's, and asthma, provides a positive market outlook. Aside from that, there is a growing demand for SNP genotyping to establish genetic relationships, resolve paternity disputes, and aid in criminal investigations around the globe. This, combined with the thriving medical industry, propels the market forward. Furthermore, the market's growth is fueled by increased demand for pharmacogenomics as the pipeline for personalized medicine and novel drug delivery systems grows.

Highlights

• Through technology, TaqMan SNP Genotyping generates the highest revenue share in the market.
• Pharmaceuticals and Pharmacogenomics contribute significantly to the market based on application.

Market Dynamics

Global Single Nucleotide Polymorphisms Genotyping Market Drivers

Increasing Prevalence of Genetic Disorders

The rising global prevalence of genetic disorders and complex diseases highlights the significance of SNP genotyping in understanding disease etiology, genetic susceptibility, and disease progression. Genome-wide association studies (GWAS) use SNP genotyping data to identify genetic variants associated with cancer, cardiovascular disease, autoimmune disorders, and neurological disorders, increasing demand for genotyping services and platforms. According to the World Health Organization (WHO), genetic disorders contribute significantly to the global disease burden, affecting millions of people and families. According to the CDC, genetic disorders and congenital abnormalities affect approximately 2%-5% of all live births. They are also responsible for 20-30% of infant deaths. 

Furthermore, cystic fibrosis, sickle cell disease, Huntington's disease, and hereditary cancers are all well-documented conditions caused by pathogenic genetic variants. The prevalence of genetic disorders varies greatly across populations and geographic regions, owing to genetic diversity, consanguinity rates, and environmental exposure. China has the world's highest prevalence of rare genetic diseases, with over 10 million people affected by chromosome disease syndromes and over 1 million by monogenic diseases. As of the end of September 2023, China had registered approximately 780,000 rare disease cases. In India, more than 1.7 million children are born with congenital disabilities each year. 

As a result, the rising prevalence of genetic disorders emphasizes the significance of SNP genotyping in understanding disease etiology, identifying disease-associated genetic variants, and guiding personalized healthcare interventions. Researchers and clinicians can use genotyping technologies to improve diagnostic accuracy, optimize treatment strategies, and improve patient outcomes in managing genetic disorders. 

Global Single Nucleotide Polymorphisms Genotyping Market Restraints

High Cost of Genotyping Platforms and Assays

The initial investment required to acquire SNP genotyping platforms, instruments, and reagents can be significant, especially for high-throughput systems and advanced technologies like next-generation sequencing (NGS). Furthermore, the recurring costs of consumables, maintenance, and data analysis software can strain the budgets of research laboratories, academic institutions, and clinical facilities, limiting the adoption and accessibility of genotyping technologies, particularly in resource-constrained environments.

Moreover, the cost of genotyping platforms varies depending on the technology used (e.g., microarray-based, PCR-based, sequencing-based), throughput capacity, and level of automation. High-throughput systems processing thousands to millions of SNP markers at once typically have higher initial costs than low-throughput or manual methods. For example, SNP assays cost between USD 200 and USD 375 and can handle up to 1500 samples. There is also a volume-dependent charge that begins at USD 0.85 for each requested genotype.

Hence, the high cost of genotyping platforms and assays may discourage smaller research laboratories, academic institutions, and resource-constrained settings from implementing SNP genotyping technologies, limiting access to genomic analysis capabilities. Furthermore, advances in multiplexing technologies, assay miniaturization, and lab automation aim to lower per-sample costs and increase throughput efficiency, making genotyping technologies more accessible and cost-effective for various applications and end users.

Global Single Nucleotide Polymorphisms Genotyping Market Opportunity

Expansion of Personalized Medicine

As understanding the genetic basis of diseases advances, there is a growing interest in personalized medicine approaches that use SNP genotyping data to tailor treatments to individual patients. Incorporating genotyping technologies into clinical practice allows healthcare providers to identify genetic variants associated with drug response, disease risk, and treatment outcomes, allowing for more targeted and effective therapeutic interventions. Genotyping providers can collaborate with healthcare institutions, pharmaceutical companies, and regulatory agencies to advance personalized medicine and improve patient outcomes. In November 2022, for example, the Cleveland Clinic expanded its cutting-edge genetic testing platform for cancer patients, making it the standard treatment option. Whole-exome sequencing, which examines all other genome regions, has increased the ability to analyze genomic content in tumor tissue samples. 

In 2023, the first CRISPR-based gene-editing therapy was approved. Gene editing can remove, insert, or modify parts of our genetic code. Advances in genomics, including SNP genotyping technologies, have fueled the growth of personalized medicine approaches, allowing healthcare providers to identify genetic variants linked to disease susceptibility, drug response, and treatment outcomes. Genome-wide association studies (GWAS) use SNP genotyping data to identify genetic markers associated with complex diseases, which aids in developing targeted therapies and precision medicine interventions.

Regional Analysis

The global single nucleotide polymorphisms genotyping market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global single nucleotide polymorphisms genotyping market shareholder and is estimated to grow at a CAGR of 10.3% over the forecast period. Some factors driving the North American single nucleotide polymorphism (SNP) genotyping market included favorable government policies for proper diagnosis, increased screening and treatment of fatal diseases, improved research and development (R&D) facilities, etc. The United States is expected to grow and change significantly in North America. The steadily rising number of chronic illnesses in the United States will likely increase demand for genotyping tools and services. According to the most recent version of the article Chronic Diseases in America, which was published by the National Center for Chronic Disease Prevention and Health Promotion in January 2021, six out of every ten adults in the United States have at least one chronic disease, with four out of every ten adults having two or more. Genotyping techniques can be used to identify and treat chronic diseases early.

Additionally, in the United States, the healthcare industry is heavily invested in innovative solutions, such as genotyping, to improve the development of advanced disease diagnoses to aid patient care. National Institutes of Health (NIH) data shows that cancer genomics has received increasing funding. In 2021, it received financing totaling up to USD 1,116 million. The abundance of available money is a significant factor driving market growth. 

Europe is anticipated to exhibit a CAGR of 10.4% over the forecast period. European countries, on the other hand, are at the forefront of genetic research, with renowned academic institutions, research centers, and biotechnology companies propelling genomics and personalized medicine forward. For example, the UK Biobank (UKB) conducts genome-wide genotyping, or SNP profiling, on its participants. The UKB's Axiom Array detects approximately 850,000 variants before using the Haplotype Reference Consortium and UK10K + 1000 Genomes reference panels to infer over 90 million additional variants. The UKB's whole genome sequencing data will assist researchers in developing new treatments for diseases such as heart disease, type 2 diabetes, rare genetic diseases, and cancer. Researchers can, for example, use genetic variation in people predisposed to a specific disease to identify potential drug targets. 

Furthermore, the European market benefits from government initiatives, research funding, and collaborative networks that promote genomic research and personalized medicine initiatives. 

The Asia-Pacific region is expected to mimic growth in the global SNP genotyping market based on similar characteristics in several countries, as the area is also known to have persistent unmet medical needs. The growth trajectory is also expected to be accompanied by increased mindfulness of advanced sequencing techniques. Furthermore, APAC countries such as China, Japan, India, and South Korea are experiencing increased genomic research, clinical diagnostics, and agricultural biotechnology applications, driving demand for SNP genotyping technologies and services. 

In addition, industry behemoths in the global SNP genotyping market are gradually diversifying their position through significant geographical expansion into emerging countries. 

Segmental Analysis

The global single nucleotide polymorphisms genotyping market is segmented based on technology and application.

The market is further segmented by technology into TaqMan SNP Genotyping, Massarray SNP Genotyping, and SNP GeneChip Arrays. 

TaqMan SNP genotyping is a popular PCR-based approach for detecting single nucleotide polymorphisms (SNPs). This assay employs allele-specific TaqMan probes labeled with fluorescent dyes, which selectively hybridize to the target SNP alleles during PCR amplification. The samples' genotypes can be determined by measuring the fluorescence signals emitted by the probes. TaqMan assays are particular, sensitive, and scalable, making them appropriate for small-scale and high-throughput genotyping applications. They are widely used in research, clinical diagnostics, and pharmacogenomics studies because of their dependability and ease of use. Agena Bioscience (formerly Sequenom) developed MassARRAY SNP genotyping, a mass spectrometry-based SNP analysis method. MALDI-TOF MS is used to detect allele-specific primer extension products. MassARRAY assays have a high multiplexing capability, allowing the analysis of multiple SNPs in a single reaction. They provide accurate and reliable high-resolution and sensitivity genotyping results, making them suitable for various applications, including population genetics, GWAS, and clinical research. 

The market can be bifurcated by application into Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, and Agricultural Biotechnology.

Pharmaceuticals and pharmacogenomics held the largest market share. In pharmaceuticals and pharmacogenomics, SNP genotyping is used to investigate how genetic variations affect drug response, metabolism, and toxicity in individuals. Pharmacogenomic testing allows healthcare providers to tailor drug treatments to patients' genetic profiles, resulting in better therapeutic outcomes and fewer adverse reactions. SNP genotyping is used in drug development pipelines to identify targets, stratify patients in clinical trials, and discover pharmacogenomic biomarkers that will guide precision medicine approaches.

Furthermore, according to a CDC update from April 2022, an examination of the Pharmacogenomics database revealed significant translation and implementation science growth over the last decade. In 2021, the number of published studies in these areas rose to 261. According to an article by Frontiers Media SA in August 2021, SNP-based Pharmacogenomics testing was the most commonly used test for clinical Pharmacogenomics profiling of individuals. Furthermore, specific genotyping methods primarily use various SNP-based approaches, such as real-time PCR with TaqMan probes and the restriction fragment length polymorphism (RFLP) technique. Gene panel-based genotyping methods, such as ADME arrays, are also used in everyday clinical practice. 

In diagnostic research, SNP genotyping is used to identify genetic variations associated with human diseases, inherited disorders, and susceptibility to common complex diseases. Genome-wide association studies (GWAS) use SNP genotyping data to identify genetic risk factors for cancer, cardiovascular disease, and neurological conditions. Furthermore, SNP genotyping is used in clinical diagnostics to molecularly profile patients, assess disease risk, and plan personalized treatment based on individual genetic profiles.

Recent Developments

• April 2024- Agilent received European IVDR Class C certification for the GenetiSure Dx Postnatal Assay.
• April 2024- Eurofins Genomics AgriGenomics Europe, an internationally leading provider of DNA sequencing and genotyping services, and Gencove, a pioneer in low-pass whole genome sequencing (lpWGS) imputation and analysis, announced a collaboration to provide a comprehensive lpWGS solution in Europe, delivering high-throughput and cost-effective sequencing. The partnership will bring Gencove's data analytics and management platform together with Eurofins Genomics AgriGenomics Europe's low-pass whole genomics sequencing capabilities, ushering in a new era of genotyping. 
• April 2024- The European Commission approved Illumina's planned divestment of GRAIL.
• March 2024- Integrated DNA Technologies launched a new custom vector onboarding tool to improve gene synthesis.
• January 2024- LGC Biosearch Technologies™ introduced sbeadex™ Lightning, a novel nucleic acid extraction method, at the San Diego International Plant and Animal Genome Conference (PAG). This ground-breaking product quickly delivers high-purity DNA in high yields, with results typically achieved in 5 minutes - from lysate to eluate - for both plant and animal samples.